Medaimun GmbH   Report issue

For profit Phase 2 Phase 4
Founded: Frankfurt Germany (2012)

Organization Overview

First Clinical Trial
2014
NCT02515799
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Medaimun GmbH

Active Ingredients

Drugs in Phase 4 Trials (1)

tyloxapol (1 trial)

Drugs in Phase 2 Trials (1)

tregalizumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 4)

Bronchitis (Phase 4)

Bronchitis, Chronic (Phase 4)

Inflammation (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2